Shares of Pharvaris (NASDAQ:PHVS - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $15.01, but opened at $15.40. Pharvaris shares last traded at $15.10, with a volume of 6,043 shares trading hands.
Analysts Set New Price Targets
Separately, JMP Securities increased their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.
Read Our Latest Stock Analysis on PHVS
Pharvaris Stock Performance
The firm's 50 day moving average price is $17.13 and its two-hundred day moving average price is $19.11. The firm has a market cap of $871.67 million, a PE ratio of -5.95 and a beta of -3.02.
Institutional Trading of Pharvaris
Several hedge funds have recently made changes to their positions in PHVS. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris in the 3rd quarter valued at approximately $57,000. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after buying an additional 2,847 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Pharvaris in the 4th quarter valued at approximately $64,000. Barclays PLC purchased a new stake in shares of Pharvaris in the 3rd quarter valued at approximately $106,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Pharvaris during the 4th quarter worth approximately $111,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Articles
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
